In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Veracyte Inc (NASDAQ: VCYT) closed at $26.82 in the last session, up 0.22% from day before closing price of $26.76. In other words, the price has increased by $0.22 from its previous closing price. On the day, 0.69 million shares were traded. VCYT stock price reached its highest trading level at $27.11 during the session, while it also had its lowest trading level at $25.99.
Ratios:
We take a closer look at VCYT’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.77. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 5.10. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on March 20, 2025, initiated with a Buy rating and assigned the stock a target price of $45.
On December 05, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $38 to $37.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $50 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when EASTHAM KARIN sold 4,590 shares for $26.66 per share. The transaction valued at 122,388 led to the insider holds 13,907 shares of the business.
Bhanji Muna sold 4,589 shares of VCYT for $122,367 on Jun 13 ’25. The Director now owns 29,989 shares after completing the transaction at $26.67 per share. On Jun 13 ’25, another insider, KARIN EASTHAM, who serves as the Director of the company, bought 4,590 shares for $26.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 2100397568 and an Enterprise Value of 1863543808. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.93, and their Forward P/E ratio for the next fiscal year is 37.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.53 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 4.022 whereas that against EBITDA is 29.922.
Stock Price History:
The Beta on a monthly basis for VCYT is 2.09, which has changed by 0.2325368 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $47.32, while it has fallen to a 52-week low of $19.73. The 50-Day Moving Average of the stock is -8.24%, while the 200-Day Moving Average is calculated to be -23.32%.
Shares Statistics:
According to the various share statistics, VCYT traded on average about 1.01M shares per day over the past 3-months and 884800 shares per day over the past 10 days. A total of 78.31M shares are outstanding, with a floating share count of 77.23M. Insiders hold about 1.39% of the company’s shares, while institutions hold 108.03% stake in the company. Shares short for VCYT as of 1748563200 were 5469491 with a Short Ratio of 5.43, compared to 1745971200 on 5566844. Therefore, it implies a Short% of Shares Outstanding of 5469491 and a Short% of Float of 7.79.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Veracyte Inc (VCYT) in the stock market is under the watchful eye of 9.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.32, with high estimates of $0.36 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.39 and $1.19 for the fiscal current year, implying an average EPS of $1.3. EPS for the following year is $1.34, with 10.0 analysts recommending between $1.51 and $1.04.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $120.9M. It ranges from a high estimate of $123.4M to a low estimate of $116.9M. As of the current estimate, Veracyte Inc’s year-ago sales were $114.43MFor the next quarter, 9 analysts are estimating revenue of $124.35M. There is a high estimate of $129M for the next quarter, whereas the lowest estimate is $121M.
A total of 10 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $497.8M, while the lowest revenue estimate was $482.1M, resulting in an average revenue estimate of $491.92M. In the same quarter a year ago, actual revenue was $445.76MBased on 10 analysts’ estimates, the company’s revenue will be $540.61M in the next fiscal year. The high estimate is $557.91M and the low estimate is $508.7M.
